Warm versus cold blood cardioplegia in paediatric congenital heart surgery: a randomized trial.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
03 04 2023
Historique:
received: 20 07 2022
revised: 06 12 2022
medline: 14 4 2023
pubmed: 18 2 2023
entrez: 17 2 2023
Statut: ppublish

Résumé

Intermittent cold blood cardioplegia is commonly used in children, whereas intermittent warm blood cardioplegia is widely used in adults. We aimed to compare clinical and biochemical outcomes with these 2 methods. A single-centre, randomized controlled trial was conducted to compare the effectiveness of warm (≥34°C) versus cold (4-6°C) antegrade cardioplegia in children. The primary outcome was cardiac troponin T over the 1st 48 postoperative hours. Intensive care teams were blinded to group allocation. Outcomes were compared by intention-to-treat using linear mixed-effects, logistic or Cox regression. 97 participants with median age of 1.2 years were randomized (49 to warm, 48 to cold cardioplegia); 59 participants (61%) had a risk-adjusted congenital heart surgery score of 3 or above. There were no deaths and 92 participants were followed to 3-months. Troponin release was similar in both groups [geometric mean ratio 1.07; 95% confidence interval (CI) 0.79-1.44; P = 0.66], as were other cardiac function measures (echocardiography, arterial and venous blood gases, vasoactive-inotrope score, arrhythmias). Intensive care stay was on average 14.6 h longer in the warm group (hazard ratio 0.52; 95% CI 0.34-0.79; P = 0.003), with a trend towards longer overall hospital stays (hazard ratio 0.66; 95% CI 0.43-1.02; P = 0.060) compared with the cold group. This could be related to more unplanned reoperations on bypass in the warm group compared to cold group (3 vs 1). Warm blood cardioplegia is a safe and reproducible technique but does not provide superior myocardial protection in paediatric heart surgery.

Identifiants

pubmed: 36799559
pii: 7043977
doi: 10.1093/ejcts/ezad041
pmc: PMC10097434
pii:
doi:

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : British Heart Foundation
ID : CH/17/1/32804
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/1992027/7163
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/14/72/31080
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/15/33/31394/BHF
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.

Références

Eur J Cardiothorac Surg. 2011 Dec;40(6):1384-90
pubmed: 21752665
J Thorac Cardiovasc Surg. 2011 Nov;142(5):1114-21, 1121.e1-2
pubmed: 21872282
Pediatr Crit Care Med. 2010 Mar;11(2):234-8
pubmed: 19794327
Heart. 2019 Mar;105(6):455-464
pubmed: 30322847
Ann Thorac Surg. 2013 Sep;96(3):923-9
pubmed: 23915588
J Thorac Cardiovasc Surg. 2007 Jan;133(1):241-6
pubmed: 17198820
Front Pediatr. 2021 Dec 14;9:757551
pubmed: 34970516
Perfusion. 2019 Mar;34(2):125-129
pubmed: 30095360
Interact Cardiovasc Thorac Surg. 2019 Jan 1;28(1):144-150
pubmed: 29947787
BMJ Open. 2020 Oct 14;10(10):e036974
pubmed: 33055113
J Thorac Cardiovasc Surg. 2021 Mar;161(3):1155-1166.e9
pubmed: 33419533
Ann Thorac Surg. 2016 Apr;101(4):1522-9
pubmed: 26921979
Ann Thorac Surg. 2017 Jun;103(6):1956-1962
pubmed: 28262296
J Thorac Cardiovasc Surg. 1977 Jan;73(1):87-94
pubmed: 831012

Auteurs

Serban Stoica (S)

Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Helena J M Smartt (HJM)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

Rachael Heys (R)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

Karen Sheehan (K)

Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

Terrie Walker-Smith (T)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

Andrew Parry (A)

Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Richard Beringer (R)

Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Iakovos Ttofi (I)

Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Rebecca Evans (R)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

Lucy Dabner (L)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

Mohamed T Ghorbel (MT)

Bristol Heart Institute, University of Bristol, Bristol, UK.

William Lansdowne (W)

Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Barnaby C Reeves (BC)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

Gianni D Angelini (GD)

National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.
Bristol Heart Institute, University of Bristol, Bristol, UK.

Chris A Rogers (CA)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK.
National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

Massimo Caputo (M)

Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Bristol Heart Institute, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH